The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Lactoferricin’s Role in Preventing Disc Degeneration

Lactoferricin’s Role in Preventing Disc Degeneration

September 16, 2013 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Results from a recent study suggest that the combination of bone-morphogenetic protein-7 (BMP7) and lactoferricin B (LfcinB) may be a useful treatment for disc degeneration.

You Might Also Like
  • Infiltrating the Disc: Mast Cells & Back Pain
  • Study Uncovers Tet2’s Role in Resolving Inflammation
  • EULAR 2012: MicroRNAs’ Role in Rheumatic Diseases Coming into Sharper Focus
Also By This Author
  • Healthcare Providers Should Encourage Exercise for OA Patients

LfcinB is a 25-amino acid lactoferrin (Lf) peptide that has antiinflammatory and anticancer properties. Lf is found in high concentrations in colostrum. Commercial Lf is typically isolated from bovine milk.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Michael B. Ellman, MD, at Rush University Medical Center in Chicago, and colleagues published their LfcinB research in Gene.1 The work builds on the team’s previous research describing the anabolic and catabolic mediators of disc degeneration. The previous studies suggested that LfcinB-mediated activation of the ERK/MAPK-Sp1 axis is important for disc nucleus pulposus cells.

Other researchers have published promising results indicating that therapies with individual growth factors such as Lf, LfcinB, and BMP7 may be useful in the treatment of musculoskeletal diseases. For example, BMP7 activity in the vertebral disc is enhanced by insulin-like growth factor–a (IGF-1), and the result is a shift in homeostasis to a pro-anabolic state.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the current study, the investigators describe the molecular mechanism by which LfcinB enhances biological anabolism when combined with BMP7. While the combined effect of LfcinB and BMP7 is significant, the research was performed in vitro and work still needs to be done to determine the efficacy of the treatment in vivo. The in vivo study will soon be underway.

“We anticipate a positive systemic impact that may prevent or decrease further joint deterioration,” explained Hee-Jeong Im, PhD, corresponding author of the study. “The good thing about lactoferrin/lactoferricin is that you can take it orally and you don’t have to inject.”

Both LfcinB and Lf are stable and inexpensive. They also have a good safety profile.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Im explained that her broader interest is in using LfcinB to enhance the probiotic system. “We are interested in adjuvant therapies including those involving probiotics because the mechanistic differences in their actions promote synergism,” elaborated Dr. Im. She is hopeful that a combination of LfcinB and probiotics can improve joint health.

Dr. Im described the low-grade inflammation that underscores not just rheumatoid arthritis, but also osteoarthritis (OA). Many patients with OA have excess fat tissue that produces excess inflammatory cytokines thereby contributing to disease. The hope is that LfcinB and/or Lf can be ingested as a form of preventive medicine to counter the induction of low-grade inflammation in the body. If LfcinB is able to prevent systemic low-grade inflammation, it may also be able to influence the course of other diseases, including Alzheimer’s disease and cancer.

Pages: 1 2 | Single Page

Filed Under: Conditions, Osteoarthritis, Research Reviews Tagged With: bone-morphogenetic protein, disc degeneration, inflammation, lactoferricin

You Might Also Like:
  • Infiltrating the Disc: Mast Cells & Back Pain
  • Study Uncovers Tet2’s Role in Resolving Inflammation
  • EULAR 2012: MicroRNAs’ Role in Rheumatic Diseases Coming into Sharper Focus
  • 2014 ACR/ARHP Annual Meeting: Fat’s Role in Inflammation

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.